Registrieren

Mumbai-based Wockhardt has struck success in its innovative research on a range of antibiotic drugs, bridging a global pipeline gap for difficult-to-treat infections. In May this year, the company secured approvals from Indian and US drug regulators for a breakthrough drug, Zaynich (cefepime + zidebactam), to treat complicated urinary tract infection, including acute pyelonephritis or severe kidney infections. Wockhardt has showcased six drugs to treat antimicrobial resistance (AMR).